Mabwell Biotech’s net profit loss in 2024 was 1.067 billion yuan
February 28, 2025
Source: drugdu
29
On the evening of February 26, Mabwell Biotech (688062) released its 2024 performance report, showing that the company achieved operating income of 199 million yuan, a year-on-year increase of 55.5%; attributable to -1.067 billion yuan, compared with -1.053 billion yuan in the same period last year.
Mabwell Biotech said that according to the report layout, the company's operating income increased from the same period last year. The main reason is that the company actively expanded the market, and the sales of the drug Mai Lishu increased significantly compared with the same period last year. At the same time, the drug Mabwell Health was approved for listing in March 2024. The sales revenue of drugs in the same period of this report increased; with the further expansion of commercialization, operating costs and sales expenses increased accordingly; at the same time, with the continuous advancement of new drug research and development, many innovative drugs are in the key trial research stage, and the overall R&D investment remains at the recent level.
https://finance.eastmoney.com/a/202502263330595194.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- 1st and only one! 1 Medical Device Approved by FDA February 28, 2025
- Revolutionizing Medical B2B Trade with AI-Powered Intelligence February 28, 2025
- Aimi Vaccines has been approved by the FDA to conduct clinical trials of mRNA vaccines February 28, 2025
- Clinical data of Orelabrutinib for the treatment of MS released February 28, 2025
- Innovative treatments for ALS, updated progress February 28, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
